2015
DOI: 10.15761/icst.1000141
|View full text |Cite
|
Sign up to set email alerts
|

Single dose bevacizumab as treatment for symptomatic, corticosteroid-refractory pseudoprogression after chemoradiation therapy for newly diagnosed glioblastoma: A case report

Abstract: The survival of patients with glioblastoma has improved significantly since the introduction of radiation therapy with concurrent and adjuvant temolozolomide as standard therapy. However, symptomatic increases in MRI enhancement and edema mimicking tumor progression (pseudoprogression) have been well described after dual modality chemoradiation. We report the outcome of a glioblastoma patient after the administration of a single dose of bevacizumab for corticosteroidrefractory pseudoprogression. A 60-year old … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals

citations
Cited by 0 publications
references
References 24 publications
0
0
0
Order By: Relevance

No citations

Set email alert for when this publication receives citations?